Matthew Kelly
Concepts (271)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumococcal Infections | 7 | 2025 | 14 | 4.870 |
Why?
| | Nasopharynx | 10 | 2025 | 34 | 4.240 |
Why?
| | Respiratory Tract Infections | 6 | 2025 | 81 | 3.390 |
Why?
| | Pneumococcal Vaccines | 6 | 2025 | 16 | 3.010 |
Why?
| | Hematopoietic Stem Cell Transplantation | 7 | 2024 | 606 | 2.770 |
Why?
| | Pneumonia | 6 | 2021 | 125 | 2.690 |
Why?
| | HIV Infections | 6 | 2025 | 388 | 2.430 |
Why?
| | Botswana | 17 | 2025 | 32 | 2.320 |
Why?
| | Streptococcus pneumoniae | 5 | 2025 | 26 | 2.210 |
Why?
| | Infant | 30 | 2025 | 3684 | 2.130 |
Why?
| | Phylogeny | 4 | 2025 | 234 | 2.110 |
Why?
| | Bacteria | 8 | 2025 | 220 | 2.090 |
Why?
| | Child | 31 | 2025 | 7157 | 1.830 |
Why?
| | Communicable Diseases | 3 | 2024 | 55 | 1.810 |
Why?
| | Antibodies, Neutralizing | 5 | 2025 | 79 | 1.790 |
Why?
| | Antibodies, Viral | 5 | 2025 | 110 | 1.790 |
Why?
| | Corynebacterium | 4 | 2025 | 5 | 1.630 |
Why?
| | RNA, Ribosomal, 16S | 4 | 2025 | 115 | 1.490 |
Why?
| | Graft vs Host Disease | 2 | 2024 | 88 | 1.470 |
Why?
| | Humans | 69 | 2025 | 52336 | 1.420 |
Why?
| | Anti-Bacterial Agents | 9 | 2024 | 801 | 1.340 |
Why?
| | Bacterial Typing Techniques | 3 | 2025 | 37 | 1.320 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2022 | 39 | 1.270 |
Why?
| | Prospective Studies | 13 | 2025 | 2428 | 1.180 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2020 | 81 | 1.180 |
Why?
| | Base Composition | 2 | 2025 | 24 | 1.150 |
Why?
| | Nucleic Acid Hybridization | 2 | 2025 | 57 | 1.140 |
Why?
| | DNA, Bacterial | 2 | 2025 | 176 | 1.100 |
Why?
| | Child, Preschool | 15 | 2025 | 4030 | 1.090 |
Why?
| | Sepsis | 3 | 2023 | 229 | 1.090 |
Why?
| | Fatty Acids | 2 | 2025 | 151 | 1.080 |
Why?
| | Sequence Analysis, DNA | 2 | 2025 | 230 | 1.060 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2022 | 14 | 1.040 |
Why?
| | Organ Transplantation | 2 | 2024 | 50 | 1.040 |
Why?
| | Infant, Newborn | 14 | 2025 | 2826 | 1.010 |
Why?
| | Serotyping | 2 | 2024 | 12 | 0.990 |
Why?
| | Respiratory System | 1 | 2025 | 28 | 0.950 |
Why?
| | Female | 34 | 2025 | 28105 | 0.940 |
Why?
| | Male | 34 | 2025 | 26696 | 0.940 |
Why?
| | Bacterial Infections | 3 | 2023 | 98 | 0.920 |
Why?
| | Quality of Life | 3 | 2025 | 868 | 0.890 |
Why?
| | Carnobacteriaceae | 1 | 2024 | 1 | 0.880 |
Why?
| | Gram-Positive Cocci | 1 | 2024 | 3 | 0.880 |
Why?
| | Microbial Sensitivity Tests | 2 | 2024 | 286 | 0.860 |
Why?
| | Catheter-Related Infections | 2 | 2014 | 51 | 0.840 |
Why?
| | Drug Resistance, Bacterial | 2 | 2024 | 81 | 0.830 |
Why?
| | Anti-Infective Agents | 2 | 2023 | 106 | 0.800 |
Why?
| | Clostridium Infections | 1 | 2023 | 55 | 0.790 |
Why?
| | Feces | 4 | 2025 | 154 | 0.760 |
Why?
| | Haemophilus influenzae type b | 1 | 2021 | 1 | 0.740 |
Why?
| | Transplantation, Homologous | 2 | 2020 | 150 | 0.740 |
Why?
| | Haemophilus Vaccines | 1 | 2021 | 3 | 0.740 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2021 | 11 | 0.730 |
Why?
| | Genome, Bacterial | 3 | 2025 | 60 | 0.680 |
Why?
| | Maternal-Fetal Exchange | 1 | 2020 | 48 | 0.670 |
Why?
| | Health Status Disparities | 1 | 2023 | 216 | 0.660 |
Why?
| | Culture Media | 1 | 2020 | 98 | 0.660 |
Why?
| | Specimen Handling | 1 | 2020 | 56 | 0.660 |
Why?
| | Spinal Cord Stimulation | 1 | 2020 | 43 | 0.660 |
Why?
| | Radiography, Thoracic | 2 | 2020 | 66 | 0.650 |
Why?
| | Cryopreservation | 1 | 2020 | 41 | 0.650 |
Why?
| | Cytomegalovirus Infections | 2 | 2020 | 36 | 0.650 |
Why?
| | Cohort Studies | 8 | 2024 | 1532 | 0.640 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 177 | 0.630 |
Why?
| | Adolescent | 11 | 2025 | 6692 | 0.620 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2020 | 61 | 0.620 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2018 | 9 | 0.610 |
Why?
| | Carrier State | 1 | 2018 | 10 | 0.610 |
Why?
| | Autopsy | 1 | 2018 | 48 | 0.590 |
Why?
| | Chronic Pain | 1 | 2020 | 178 | 0.580 |
Why?
| | Intestinal Mucosa | 1 | 2019 | 224 | 0.570 |
Why?
| | Asthma | 1 | 2022 | 316 | 0.570 |
Why?
| | Transplantation Conditioning | 1 | 2018 | 93 | 0.560 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2019 | 196 | 0.530 |
Why?
| | Retrospective Studies | 11 | 2023 | 6578 | 0.510 |
Why?
| | Cytomegalovirus | 1 | 2015 | 30 | 0.490 |
Why?
| | Candidiasis, Invasive | 1 | 2014 | 11 | 0.460 |
Why?
| | HIV Seropositivity | 1 | 2014 | 28 | 0.450 |
Why?
| | Gestational Age | 2 | 2016 | 412 | 0.430 |
Why?
| | United States | 6 | 2025 | 5182 | 0.400 |
Why?
| | Adult | 11 | 2025 | 14139 | 0.390 |
Why?
| | Vaccines, Conjugate | 2 | 2022 | 9 | 0.380 |
Why?
| | Young Adult | 6 | 2025 | 4319 | 0.380 |
Why?
| | Catheterization, Central Venous | 1 | 2013 | 82 | 0.380 |
Why?
| | Gastrointestinal Tract | 2 | 2023 | 108 | 0.350 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 1676 | 0.340 |
Why?
| | Transcriptome | 2 | 2025 | 367 | 0.340 |
Why?
| | Probiotics | 2 | 2022 | 24 | 0.330 |
Why?
| | Hospital Mortality | 2 | 2023 | 428 | 0.300 |
Why?
| | Adaptive Immunity | 2 | 2025 | 33 | 0.290 |
Why?
| | Case-Control Studies | 3 | 2018 | 1201 | 0.290 |
Why?
| | Pandemics | 2 | 2024 | 585 | 0.280 |
Why?
| | Breast Feeding | 2 | 2020 | 197 | 0.280 |
Why?
| | Cost-Benefit Analysis | 2 | 2025 | 269 | 0.270 |
Why?
| | Risk Factors | 6 | 2020 | 3872 | 0.270 |
Why?
| | Treatment Failure | 2 | 2019 | 122 | 0.260 |
Why?
| | Length of Stay | 2 | 2020 | 659 | 0.250 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 12 | 0.240 |
Why?
| | Tyrosine | 1 | 2025 | 88 | 0.240 |
Why?
| | Haemophilus influenzae | 1 | 2025 | 16 | 0.240 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2025 | 55 | 0.240 |
Why?
| | Quality-Adjusted Life Years | 1 | 2025 | 67 | 0.230 |
Why?
| | Tertiary Care Centers | 2 | 2016 | 82 | 0.230 |
Why?
| | Age Factors | 2 | 2025 | 1127 | 0.230 |
Why?
| | Otitis Media | 1 | 2025 | 30 | 0.230 |
Why?
| | B-Lymphocytes | 1 | 2025 | 185 | 0.220 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2016 | 136 | 0.220 |
Why?
| | Fluoroquinolones | 1 | 2024 | 25 | 0.220 |
Why?
| | Hospitalization | 2 | 2021 | 732 | 0.220 |
Why?
| | Immune System | 1 | 2024 | 41 | 0.220 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2025 | 165 | 0.220 |
Why?
| | Immunity, Innate | 1 | 2025 | 117 | 0.220 |
Why?
| | Disease Susceptibility | 1 | 2024 | 96 | 0.210 |
Why?
| | Immunotherapy, Adoptive | 1 | 2025 | 167 | 0.210 |
Why?
| | Vaccines | 1 | 2024 | 51 | 0.210 |
Why?
| | Prevalence | 2 | 2024 | 1007 | 0.210 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2023 | 45 | 0.210 |
Why?
| | Pneumonia, Bacterial | 2 | 2021 | 30 | 0.200 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2023 | 11 | 0.200 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2022 | 3 | 0.200 |
Why?
| | Caregivers | 2 | 2023 | 238 | 0.200 |
Why?
| | Treatment Outcome | 4 | 2025 | 5407 | 0.200 |
Why?
| | DiGeorge Syndrome | 1 | 2023 | 20 | 0.200 |
Why?
| | Health Status | 1 | 2025 | 295 | 0.200 |
Why?
| | Educational Status | 1 | 2024 | 227 | 0.200 |
Why?
| | Lymphoproliferative Disorders | 1 | 2022 | 27 | 0.200 |
Why?
| | Hypertension, Portal | 1 | 2022 | 22 | 0.200 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 33 | 0.200 |
Why?
| | Antibodies, Bacterial | 1 | 2022 | 30 | 0.190 |
Why?
| | Infant, Very Low Birth Weight | 3 | 2020 | 51 | 0.190 |
Why?
| | Elasticity Imaging Techniques | 1 | 2022 | 29 | 0.190 |
Why?
| | Pregnancy | 2 | 2020 | 2675 | 0.190 |
Why?
| | Gastroenteritis | 1 | 2022 | 19 | 0.190 |
Why?
| | Immunoglobulin G | 1 | 2022 | 195 | 0.180 |
Why?
| | Viral Load | 1 | 2021 | 80 | 0.180 |
Why?
| | Diarrhea | 2 | 2022 | 95 | 0.180 |
Why?
| | Aged | 3 | 2025 | 10109 | 0.180 |
Why?
| | Population Surveillance | 1 | 2022 | 165 | 0.170 |
Why?
| | Kinetics | 1 | 2022 | 623 | 0.170 |
Why?
| | Pancreatic Neoplasms | 1 | 2023 | 214 | 0.170 |
Why?
| | Workflow | 1 | 2020 | 50 | 0.170 |
Why?
| | Leadership | 1 | 2021 | 104 | 0.170 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2020 | 4 | 0.170 |
Why?
| | Anaerobiosis | 1 | 2020 | 20 | 0.170 |
Why?
| | Respiratory Syncytial Viruses | 2 | 2022 | 13 | 0.170 |
Why?
| | Leukocytes, Mononuclear | 1 | 2021 | 122 | 0.170 |
Why?
| | Protons | 1 | 2021 | 71 | 0.170 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 99 | 0.170 |
Why?
| | Spinal Cord | 1 | 2020 | 132 | 0.170 |
Why?
| | Clinical Competence | 2 | 2020 | 404 | 0.170 |
Why?
| | Hearing Disorders | 1 | 2020 | 12 | 0.170 |
Why?
| | Viruses | 1 | 2020 | 24 | 0.160 |
Why?
| | Diagnostic Errors | 1 | 2020 | 68 | 0.160 |
Why?
| | Whooping Cough | 1 | 2019 | 11 | 0.160 |
Why?
| | Pain Measurement | 1 | 2020 | 257 | 0.160 |
Why?
| | Medical Laboratory Personnel | 1 | 2019 | 5 | 0.160 |
Why?
| | Growth Disorders | 1 | 2020 | 64 | 0.160 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2020 | 39 | 0.160 |
Why?
| | Linear Models | 1 | 2020 | 286 | 0.160 |
Why?
| | Aged, 80 and over | 2 | 2025 | 3391 | 0.160 |
Why?
| | Infant Nutrition Disorders | 1 | 2019 | 2 | 0.160 |
Why?
| | Opisthorchiasis | 1 | 2019 | 1 | 0.160 |
Why?
| | Praziquantel | 1 | 2019 | 3 | 0.160 |
Why?
| | Anthelmintics | 1 | 2019 | 12 | 0.160 |
Why?
| | Multivariate Analysis | 1 | 2020 | 590 | 0.150 |
Why?
| | Respiratory Therapy | 1 | 2019 | 36 | 0.150 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 179 | 0.150 |
Why?
| | Anti-HIV Agents | 1 | 2019 | 46 | 0.150 |
Why?
| | Delivery of Health Care | 1 | 2021 | 323 | 0.150 |
Why?
| | History, 21st Century | 1 | 2018 | 59 | 0.150 |
Why?
| | Program Development | 1 | 2019 | 165 | 0.150 |
Why?
| | Infant, Low Birth Weight | 1 | 2019 | 77 | 0.150 |
Why?
| | Radiology | 1 | 2020 | 134 | 0.150 |
Why?
| | History, 20th Century | 1 | 2018 | 96 | 0.150 |
Why?
| | Middle Aged | 5 | 2025 | 13014 | 0.140 |
Why?
| | Penicillanic Acid | 1 | 2017 | 21 | 0.140 |
Why?
| | Prostatic Neoplasms | 1 | 2021 | 400 | 0.140 |
Why?
| | Polymerase Chain Reaction | 1 | 2018 | 460 | 0.140 |
Why?
| | Genetic Variation | 1 | 2018 | 230 | 0.140 |
Why?
| | Coronavirus Infections | 1 | 2020 | 188 | 0.140 |
Why?
| | Cross Infection | 1 | 2017 | 93 | 0.130 |
Why?
| | Multiple Organ Failure | 1 | 2016 | 47 | 0.130 |
Why?
| | Biomedical Research | 1 | 2019 | 256 | 0.130 |
Why?
| | Survival Rate | 1 | 2018 | 940 | 0.130 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1110 | 0.120 |
Why?
| | Point-of-Care Systems | 1 | 2016 | 65 | 0.120 |
Why?
| | Coinfection | 1 | 2016 | 44 | 0.120 |
Why?
| | Metapneumovirus | 1 | 2015 | 5 | 0.120 |
Why?
| | Enterovirus | 1 | 2015 | 8 | 0.120 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2015 | 12 | 0.120 |
Why?
| | Infant Mortality | 1 | 2015 | 62 | 0.120 |
Why?
| | Interprofessional Relations | 1 | 2016 | 91 | 0.120 |
Why?
| | Rhinovirus | 1 | 2015 | 24 | 0.120 |
Why?
| | Time Factors | 2 | 2018 | 2957 | 0.120 |
Why?
| | Veterans | 1 | 2021 | 581 | 0.120 |
Why?
| | Culture Techniques | 1 | 2014 | 21 | 0.120 |
Why?
| | Propensity Score | 1 | 2015 | 155 | 0.120 |
Why?
| | Chemoprevention | 1 | 2014 | 19 | 0.120 |
Why?
| | Seasons | 1 | 2015 | 91 | 0.120 |
Why?
| | RNA, Viral | 1 | 2015 | 125 | 0.110 |
Why?
| | Ultrasonography | 1 | 2016 | 424 | 0.110 |
Why?
| | Risk | 1 | 2015 | 313 | 0.110 |
Why?
| | Odds Ratio | 1 | 2016 | 558 | 0.110 |
Why?
| | Prognosis | 1 | 2019 | 2094 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 1543 | 0.110 |
Why?
| | Referral and Consultation | 1 | 2015 | 292 | 0.100 |
Why?
| | Antifungal Agents | 1 | 2014 | 347 | 0.090 |
Why?
| | Infant, Premature | 1 | 2014 | 319 | 0.090 |
Why?
| | Animals | 2 | 2024 | 13523 | 0.090 |
Why?
| | Recurrence | 2 | 2025 | 672 | 0.080 |
Why?
| | Cytokines | 2 | 2025 | 625 | 0.080 |
Why?
| | Pilot Projects | 2 | 2025 | 719 | 0.080 |
Why?
| | Immunologic Memory | 1 | 2025 | 32 | 0.060 |
Why?
| | Logistic Models | 2 | 2019 | 920 | 0.060 |
Why?
| | Nose | 1 | 2024 | 33 | 0.060 |
Why?
| | Cilastatin | 1 | 2023 | 5 | 0.050 |
Why?
| | Acute Disease | 1 | 2025 | 374 | 0.050 |
Why?
| | Imipenem | 1 | 2023 | 10 | 0.050 |
Why?
| | Azabicyclo Compounds | 1 | 2023 | 12 | 0.050 |
Why?
| | Pancreas | 1 | 2023 | 71 | 0.050 |
Why?
| | Mycobacterium avium Complex | 1 | 2023 | 6 | 0.050 |
Why?
| | Drug Combinations | 1 | 2023 | 134 | 0.050 |
Why?
| | Vaccines, Attenuated | 1 | 2022 | 11 | 0.050 |
Why?
| | Health Expenditures | 1 | 2023 | 73 | 0.050 |
Why?
| | Genomics | 1 | 2024 | 270 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 42 | 0.050 |
Why?
| | Aspartate Aminotransferases | 1 | 2022 | 50 | 0.050 |
Why?
| | Gadolinium DTPA | 1 | 2022 | 26 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 44 | 0.050 |
Why?
| | Cough | 1 | 2022 | 55 | 0.050 |
Why?
| | Health Care Costs | 1 | 2023 | 175 | 0.050 |
Why?
| | DNA, Viral | 1 | 2022 | 138 | 0.050 |
Why?
| | New Zealand | 1 | 2021 | 21 | 0.050 |
Why?
| | Spleen | 1 | 2022 | 173 | 0.050 |
Why?
| | Iron | 1 | 2022 | 129 | 0.050 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 38 | 0.050 |
Why?
| | Income | 1 | 2022 | 103 | 0.050 |
Why?
| | Employment | 1 | 2022 | 93 | 0.050 |
Why?
| | Veterans Health | 1 | 2021 | 64 | 0.040 |
Why?
| | Biopsy | 1 | 2023 | 604 | 0.040 |
Why?
| | Lysogeny | 1 | 2020 | 2 | 0.040 |
Why?
| | Prophages | 1 | 2020 | 2 | 0.040 |
Why?
| | Bacteriolysis | 1 | 2020 | 3 | 0.040 |
Why?
| | Meconium | 1 | 2020 | 6 | 0.040 |
Why?
| | Bacteriophages | 1 | 2020 | 10 | 0.040 |
Why?
| | Inservice Training | 1 | 2020 | 30 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 241 | 0.040 |
Why?
| | Influenza, Human | 1 | 2021 | 84 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 144 | 0.040 |
Why?
| | Opisthorchis | 1 | 2019 | 1 | 0.040 |
Why?
| | Thailand | 1 | 2019 | 7 | 0.040 |
Why?
| | Sentinel Surveillance | 1 | 2019 | 10 | 0.040 |
Why?
| | Bile Duct Neoplasms | 1 | 2019 | 28 | 0.040 |
Why?
| | Cholangiocarcinoma | 1 | 2019 | 26 | 0.040 |
Why?
| | Comorbidity | 1 | 2020 | 624 | 0.040 |
Why?
| | Career Choice | 1 | 2019 | 116 | 0.040 |
Why?
| | Quality Improvement | 1 | 2020 | 222 | 0.040 |
Why?
| | Piperacillin | 1 | 2017 | 24 | 0.040 |
Why?
| | Area Under Curve | 1 | 2017 | 181 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2020 | 1021 | 0.030 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2016 | 20 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1044 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 1214 | 0.030 |
Why?
| | Likelihood Functions | 1 | 2016 | 56 | 0.030 |
Why?
| | Liver | 1 | 2022 | 1159 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2017 | 269 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2016 | 289 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 879 | 0.030 |
Why?
| | Internship and Residency | 1 | 2019 | 449 | 0.030 |
Why?
| | Signal Transduction | 1 | 2021 | 1716 | 0.030 |
Why?
| | Databases, Factual | 1 | 2016 | 706 | 0.030 |
Why?
|
|
Kelly's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|